NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Cerus Corporation (CERS) Stock Analysis

Cerus Corporation (CERS) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

CERS

$2.59

+$0.02 (+0.78%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CERS with… →

CERS Key Statistics

As of Sep 4, 2026
Trading
Open
$2.56
Previous Close
$2.57
Day's Range
2.54–2.60
52-Week Range
1.17–3.47
Volume
1.10M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.80
Valuation
Market Cap
$521.95M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.36
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.03
Financials (FY)
Revenue (FY)
$206.13M+14.35%
Net Income (FY)
−$15.63M
Profit marginThe share of revenue left as profit after all costs and taxes.
−3.06%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
201.52M
1-Year Return
+94.74%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
2.58M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CERS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+25.73%
2025+33.77%
2024−28.70%
2023−40.82%
2022−46.40%
2021−1.59%
2020+63.98%
2019−16.77%
2018+50.00%
2017−22.30%
2016 (partial year)−36.77%

As of September 4, 2026.

CERS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$206.13M−$15.63M−7.6%
2024$180.27M−$20.92M−11.6%
2023$156.37M−$37.49M−24.0%
2022$162.05M−$42.78M−26.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$206.13M$112.29M−$8.68M−$15.63M−7.6%
2024$180.27M$99.52M−$14.23M−$20.92M−11.6%
2023$156.37M$86.40M−$26.33M−$37.49M−24.0%
2022$162.05M$87.09M−$34.08M−$42.78M−26.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CERS Valuation vs Medical Devices Median

Median of 151 stocks
MetricCERSMedical Devices medianvs median
P/S ratio2.362.9821% below
Profit margin−3.06%−1.69%1.4 pts below

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Cerus Corporation (CERS) at $521.95M. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 261.

CERS last closed at $2.59 on September 4, 2026. That is +$0.02 (+0.78%) against the previous close. Over the past 52 weeks the price has ranged from $1.17 to $3.47. The latest close sits 121.37% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $206.13M. Against the prior fiscal year total of $180.27M, that is a change of +14.35%. The same year closed with a net loss of $15.63M. The reported profit margin is −3.06%. That is 1.4 percentage points below the Medical Devices median of −1.69%. Trailing earnings per share are −0.03.

Across the 4 fiscal years on file, revenue moves from $162.05M in 2022 to $206.13M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 2.36. On price-to-sales that is 20.84% below the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

The reported beta is 1.8. Annualized volatility over the trailing 10 years is 63.91%. Over the trailing twelve months the price has returned +94.74%. Across 10 years the annualized return works out at −8.59%.

Growth & Income

The record shows no dividend for CERS.

So far in 2026 the price is +25.73%. The strongest complete calendar year on file is 2020 at +63.98%; the weakest is 2022 at −46.40%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Cerus Corporation (CERS) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cerus Corporation CERS $521.95M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Cerus Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cerus Corporation

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company offers INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company also offers INTERCEPT Blood Systems for platelets plasma, and cryoprecipitation, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells intended for transfusion; INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced; and INTERCEPT Illuminator, an LED-based device for blood component treatment. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was formerly known as CERUS TECHNOLOGIES INC and changed its name to Cerus Corporation in July 1996. The company was incorporated in 1991 and is headquartered in Concord, California.

Visit website →